Discovery of MMP activated peptide-doxorubicin prodrugs as anti-tumor agents: Part I

被引：0
作者：
Han, Wei
Jiang, XiangJun
Hu, Zilun
Graciani, Nilsa
Albright, Charles F.
Yue, Eddy
Zhang, Mingzhu
Dowling, Randine
Huang, Pearl
Oliff, Allen
Copeland, Robert A.
Trainor, George L.
Combs, Andrew P.
Seitz, Steven P.
机构：
[1] Bristol Myers Squibb, Pharmaceut Res Inst, Princeton, NJ 08543 USA
[2] GlaxoSmithKline Inc, Stevenage, Herts, England
来源：
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 2006年 / 231卷
关键词：
D O I：
暂无
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
271-MEDI
引用
收藏
页数：2
相关论文
共 49 条
  • [21] Tumor-specific pH-responsive peptide-modified pH-sensitive liposomes containing doxorubicin for enhancing glioma targeting and anti-tumor activity
    Zhao, Yang
    Ren, Wei
    Zhong, Ting
    Zhang, Shuang
    Huang, Dan
    Guo, Yang
    Yao, Xin
    Wang, Chao
    Zhang, Wei-Qiang
    Zhang, Xuan
    Zhang, Qiang
    JOURNAL OF CONTROLLED RELEASE, 2016, 222 : 56 - 66
  • [22] Anti-tumor activity of naive and activated class I-restricted tumor-specific TCR-transgenic T cells.
    Dalyot-Herman, N
    Malek, TR
    FASEB JOURNAL, 1999, 13 (04) : A613 - A613
  • [23] CLINICAL IMPLICATIONS OF THE INVITRO CYTO-TOXIC ACTIVITY OF PRE-CLINICAL AND PHASE-I ANTI-TUMOR AGENTS
    HOLLAND, JC
    BAHNA, G
    MCKEGNEY, P
    SILBERFARB, P
    TROSS, S
    GLIDEWELL, O
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1980, 21 (MAR): : 354 - 354
  • [24] Role of MDA5 and interferon-I in dendritic cells for T cell expansion by anti-tumor peptide vaccines in mice
    Sultan, Hussein
    Wu, Juan
    Kumai, Takumi
    Salazar, Andres M.
    Celis, Esteban
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2018, 67 (07) : 1091 - 1103
  • [25] Role of MDA5 and interferon-I in dendritic cells for T cell expansion by anti-tumor peptide vaccines in mice
    Hussein Sultan
    Juan Wu
    Takumi Kumai
    Andres M. Salazar
    Esteban Celis
    Cancer Immunology, Immunotherapy, 2018, 67 : 1091 - 1103
  • [26] EFFECT OF MATRIX METALLOPROTEINASE (MMP)-3,-8,-10 AND-12 ON THE STRUCTURE AND FUNCTION OF ANTI-TUMOR NECROSIS FACTOR-ALPHA AGENTS IN INFLAMMATORY BOWEL DISEASE
    Biancheri, P.
    Di Sabatino, A.
    Snoek, S. A.
    Joe-njoku, I.
    Rovedatti, L.
    Ahmad, N.
    Corazza, G. R.
    Macdonald, T. T.
    DIGESTIVE AND LIVER DISEASE, 2011, 43 : S132 - S132
  • [27] AB308 IS AN ANTI-TIGIT ANTIBODY THAT ENHANCES IMMUNE ACTIVATION AND ANTI-TUMOR IMMUNITY ALONE AND IN COMBINATION WITH OTHER I-O THERAPEUTIC AGENTS
    Piovesan, Dana
    Lopez, Alejandra
    Schweickert, Patrick
    Soriano, Ferdie
    Cho, Soonweng
    Chen, Ada
    Singh, Hema
    Zhao, Xiaoning
    Young, Stephen
    Walker, Nigel
    Walters, Matthew
    Gauthier, Kelsey Sivick
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A280 - A280
  • [28] Treatment With Anti-Tumor Necrosis Factor Biologic Agents in Human T Lymphotropic Virus Type I-Positive Patients With Rheumatoid Arthritis
    Umekita, Kunihiko
    Hidaka, Toshihiko
    Miyauchi, Shunichi
    Ueno, Shiro
    Kubo, Kazuyoshi
    Takajo, Ichiro
    Hashiba, Yayoi
    Kai, Yasufumi
    Nagatomo, Yasuhiro
    Okayama, Akihiko
    ARTHRITIS CARE & RESEARCH, 2014, 66 (05) : 788 - 792
  • [29] Mitotic kinesin-targeted antitumor agents: Discovery, lead optimization and anti-tumor activity of a series of novel quinazolinones as inhibitors of Kinesin Spindle Protein (KSP).
    Bergnes, G
    Ha, E
    Feng, BN
    Smith, WW
    Yao, B
    Tochimoto, T
    Lewis, EP
    Lee, Y
    Moody, RS
    Finer, JT
    Turincio, RA
    Wood, KW
    Sakowicz, R
    Crompton, AM
    Chabala, JC
    Morgans, DJ
    Sigal, NH
    Sabry, JH
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2002, 223 : B140 - B140
  • [30] MOUSE AND LARGE-ANIMAL TOXICOLOGY STUDIES OF 12 ANTI-TUMOR AGENTS - RELEVANCE TO STARTING DOSE FOR PHASE-I CLINICAL-TRIALS
    PENTA, JS
    ROZENCWEIG, M
    GUARINO, AM
    MUGGIA, FM
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1979, 3 (02) : 97 - 101
12345